GYRE THERAPEUTICS, INC.
Clinical-stage biopharma developing novel drugs for liver fibrosis and pneumoconiosis.
GYRE | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 12770 HIGH BLUFF DRIVE, 92130 SAN DIEGO
- Website:
- https://www.gyretx.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Gyre Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for organ fibrosis and inflammatory diseases. A subsidiary of GNI Group Ltd., the company develops small-molecule, anti-inflammatory, and anti-fibrotic drugs. Its lead drug candidate, Hydronidone (F351), is in late-stage clinical trials for treating liver fibrosis associated with chronic hepatitis B. The company's pipeline also includes Pirfenidone Capsules, which is in a Phase 3 trial for the treatment of pneumoconiosis. Gyre aims to address serious medical conditions with significant unmet needs through its targeted therapeutic programs.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all GYRE THERAPEUTICS, INC. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for GYRE THERAPEUTICS, INC.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for GYRE THERAPEUTICS, INC. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
